Countries Japan

Ono Pharmaceutical Partners with InveniAI to Revolutionize Drug Discovery Using AI

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") has announced a strategic partnership with the AI-driven company InveniAI...

 February 22, 2024 | News

Japan Accelerates Approval Process for Groundbreaking Urothelial Cancer Treatment by Astellas

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas")  announced that Japan's Ministry of Health, Labour a...

 February 19, 2024 | News

Japan Becomes First in the World to Approve Dupixent® for Chronic Spontaneous Urticaria (CSU)

  Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth appr...

 February 17, 2024 | News

eGenesis and PorMedTec Achieve Breakthrough in Genetically Engineered Porcine Donors Production in Japan

eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan Critical milestone in establishing eGenesis ...

 February 14, 2024 | News

Otsuka's AVP-786 Falls Short in Phase 3 Trial for Alzheimer's Agitation

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and its parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) have released the t...

 February 13, 2024 | News

Sysmex and Hitachi High-Tech Collaborate on New Genetic Testing Systems

  The development of assay reagents using next-generation sequencers (NGS) has seen significant advancements in recent years. However, challenges suc...

 February 08, 2024 | News

Bruker Corporation Acquires Nanophoton Expanding Raman Microscopy Portfolio and Global Reach

Bruker Corporation announced the acquisition of Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquar...

 February 08, 2024 | News

SMC Laboratories Unveils STAM™-HCC/IO+ Mouse for Advancing Liver Cancer Drug Development in Immuno-Oncology

 The company specializes in liver-related services and has evaluated test substances in over 15 MOA categories as well as over 270 target molecules us...

 February 07, 2024 | News

Travere Therapeutics Licenses Sparsentan to Renalys Pharma for Japan, South Korea, Taiwan, and Southeast Asia

Travere Therapeutics,announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin ...

 January 29, 2024 | News

Eisai Seeks Approval in Japan for Ultrahigh-Dose Mecobalamin in ALS

This application is based on the results of JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS), a Phase III trial to evaluate e...

 January 29, 2024 | News

PRISM BioLab Secures 1.5 Billion Yen in Series C Funding for Advancing Protein-Protein Interaction Technologies

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein int...

 January 25, 2024 | News

Japan greenlights historic treatment for ultra-rare Progeria, marking a significant breakthrough in addressing rapid-aging diseases.

The Progeria Research Foundation (PRF) today announced a new milestone with the approval of Zokinvy™ (lonafarnib) by the Japanese Ministry of Health,...

 January 22, 2024 | News

Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay

In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progres...

 January 22, 2024 | News

Eisai's Fycompa Injection Approved in Japan, Paving the Way for Non-Oral Antiepileptic Treatment

Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor an...

 January 20, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close